| Cancer stem cell definitions and terminology: the devil is in the details P Valent, D Bonnet, R De Maria, T Lapidot, M Copland, JV Melo, ... Nature Reviews Cancer 12 (11), 767-775, 2012 | 808 | 2012 |
| Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction M Copland, A Hamilton, LJ Elrick, JW Baird, EK Allan, N Jordanides, ... Blood 107 (11), 4532-4539, 2006 | 807 | 2006 |
| Basal nitric oxide synthesis in essential hypertension P Forte, M Copland, LM Smith, E Milne, J Sutherland, N Benjamin The Lancet 349 (9055), 837-842, 1997 | 536 | 1997 |
| Dual targeting of p53 and c-MYC selectively eliminates leukaemic stem cells SA Abraham, LEM Hopcroft, E Carrick, ME Drotar, K Dunn, ... Nature 534 (7607), 341-346, 2016 | 237 | 2016 |
| The leukaemia stem cell: similarities, differences and clinical prospects in CML and AML D Vetrie, GV Helgason, M Copland Nature Reviews Cancer 20 (3), 158-173, 2020 | 233 | 2020 |
| Oral anticoagulation and hemorrhagic complications in an elderly population with atrial fibrillation M Copland, ID Walker, RC Tait Archives of Internal Medicine 161 (17), 2125-2128, 2001 | 206 | 2001 |
| Cancerous inhibitor of PP2A (CIP2A) at diagnosis of chronic myeloid leukemia is a critical determinant of disease progression CM Lucas, RJ Harris, A Giannoudis, M Copland, JR Slupsky, RE Clark Blood, The Journal of the American Society of Hematology 117 (24), 6660-6668, 2011 | 176 | 2011 |
| Microfluidic single cell arrays to interrogate signalling dynamics of individual, patient-derived hematopoietic stem cells SL Faley, M Copland, D Wlodkowic, W Kolch, KT Seale, JP Wikswo, ... Lab on a Chip 9 (18), 2659-2664, 2009 | 170 | 2009 |
| Personalized synthetic lethality induced by targeting RAD52 in leukemias identified by gene mutation and expression profile K Cramer-Morales, M Nieborowska-Skorska, K Scheibner, M Padget, ... Blood, The Journal of the American Society of Hematology 122 (7), 1293-1304, 2013 | 169 | 2013 |
| Targeting hedgehog in hematologic malignancy DA Irvine, M Copland Blood, The Journal of the American Society of Hematology 119 (10), 2196-2204, 2012 | 169 | 2012 |
| BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors M Copland, F Pellicano, L Richmond, EK Allan, A Hamilton, FY Lee, ... Blood, The Journal of the American Society of Hematology 111 (5), 2843-2853, 2008 | 158 | 2008 |
| Elevated nitric oxide production in rheumatoid arthritis: detection using the fasting urinary nitrate: creatinine ratio PS Grabowski, AJ England, R Dykhuizen, M Copland, N Benjamin, ... Arthritis & Rheumatism: Official Journal of the American College of …, 1996 | 152 | 1996 |
| De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial RE Clark, F Polydoros, JF Apperley, D Milojkovic, K Rothwell, C Pocock, ... The Lancet Haematology 6 (7), e375-e383, 2019 | 137 | 2019 |
| Bone marrow niche trafficking of miR-126 controls the self-renewal of leukemia stem cells in chronic myelogenous leukemia B Zhang, LXT Nguyen, L Li, D Zhao, B Kumar, H Wu, A Lin, F Pellicano, ... Nature medicine 24 (4), 450-462, 2018 | 137 | 2018 |
| Hypusination of eukaryotic initiation factor 5A (eIF5A): a novel therapeutic target in BCR-ABL–positive leukemias identified by a proteomics approach S Balabanov, A Gontarewicz, P Ziegler, U Hartmann, W Kammer, ... Blood 109 (4), 1701-1711, 2007 | 125 | 2007 |
| Effects of dasatinib on SRC kinase activity and downstream intracellular signaling in primitive chronic myelogenous leukemia hematopoietic cells H Konig, M Copland, S Chu, R Jove, TL Holyoake, R Bhatia Cancer research 68 (23), 9624-9633, 2008 | 123 | 2008 |
| De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non … RE Clark, F Polydoros, JF Apperley, D Milojkovic, C Pocock, G Smith, ... The Lancet Haematology 4 (7), e310-e316, 2017 | 122 | 2017 |
| Intermittent exposure of primitive quiescent chronic myeloid leukemia cells to granulocyte-colony stimulating factor in vitro promotes their elimination by imatinib mesylate HG Jørgensen, M Copland, EK Allan, X Jiang, A Eaves, C Eaves, ... Clinical cancer research 12 (2), 626-633, 2006 | 122 | 2006 |
| A prospective study of real-time panfungal PCR for the early diagnosis of invasive fungal infection in haemato-oncology patients NE Jordanides, EK Allan, LA McLintock, M Copland, M Devaney, ... Bone marrow transplantation 35 (4), 389-395, 2005 | 117 | 2005 |
| No strong relationship between mannan binding lectin or plasma ficolins and chemotherapy-related infections DC Kilpatrick, LA McLintock, EK Allan, M Copland, T Fujita, ... Clinical & Experimental Immunology 134 (2), 279-284, 2003 | 106 | 2003 |
